Cancers,
Год журнала:
2024,
Номер
16(13), С. 2432 - 2432
Опубликована: Июль 1, 2024
Circulating
tumor
DNA
(ctDNA),
a
fragment
of
found
in
the
bloodstream,
has
emerged
as
revolutionary
tool
cancer
management.
This
review
delves
into
biology
ctDNA,
examining
release
mechanisms,
including
necrosis,
apoptosis,
and
active
secretion,
all
which
offer
information
about
state
nature
tumor.
Comprehensive
profiling
been
enabled
by
methods
such
whole
genome
sequencing
methylation
analysis.
The
low
abundance
ctDNA
fraction
makes
alternative
techniques,
digital
PCR
targeted
next-generation
exome
sequencing,
more
valuable
accurate
for
mutation
detection.
There
are
numerous
clinical
applications
analysis,
non-invasive
liquid
biopsies
minimal
residual
disease
monitoring
to
detect
recurrence,
personalized
medicine
therapy
identification,
early
detection,
real-time
evaluation
therapeutic
response.
Integrating
analysis
routine
practice
creates
promising
avenues
successful
care,
from
diagnosis
treatment
follow-up.
Journal of Biotechnology,
Год журнала:
2023,
Номер
380, С. 20 - 28
Опубликована: Дек. 19, 2023
Cancer
stands
as
one
of
the
most
common
and
lethal
diseases,
imposing
a
substantial
burden
on
global
mortality
rates.
Breast
cancer
is
distinct
from
other
forms
in
which
it
primary
cause
death
for
women.
Early
detection
breast
can
significantly
lower
risk
mortality,
improving
prognosis
those
who
are
affected.
The
rate
has
been
steadily
rising,
according
to
epidemiological
data,
especially
since
COVID-19
pandemic.
This
emphasizes
necessity
sensitive
precise
technologies
that
be
utilized
early
diagnosis.
In
this
process,
biomarkers
play
pivotal
role
by
facilitating
diagnosis
cancer.
Currently,
wide
variety
have
identified,
accuracy
These
applied
liquid
biopsies
well
solid
tissues.
context
cancer,
particularly
valuable
determining
predisposed
disease,
predicting
at
time
diagnosis,
selecting
best
course
therapy.
review
comprehensively
explores
recently
developed
gene-based
biofluids
used
conventional
cutting-edge
techniques
employed
The Journal of Liquid Biopsy,
Год журнала:
2024,
Номер
4, С. 100140 - 100140
Опубликована: Янв. 17, 2024
Liquid
biopsy
profiling
of
circulating
tumor
DNA
(ctDNA)
has
become
established
as
a
compelling,
pragmatic
diagnostic
in
the
care
cancer
patients
and
is
now
endorsed
by
multiple
guidelines.
Moreover,
ctDNA
technologies
have
advanced
significantly
offer
increasingly
comprehensive
reliable
insights
into
cancer.
In
this
review,
we
focus
on
applications
propose
that
critical
untapped
opportunity
considering
how
utilize
these
accessible,
scalable
across
diverse
potential
applications.
With
specific
clinical
applications,
rather
than
research
uses,
describe
10
use
cases
for
four
categories:
(1)
(2)
emerging
therapy
selection,
(3)
incidental
detection
secondary
genomic
findings,
(4)
quantification
plasma
content.
Cancers,
Год журнала:
2024,
Номер
16(13), С. 2432 - 2432
Опубликована: Июль 1, 2024
Circulating
tumor
DNA
(ctDNA),
a
fragment
of
found
in
the
bloodstream,
has
emerged
as
revolutionary
tool
cancer
management.
This
review
delves
into
biology
ctDNA,
examining
release
mechanisms,
including
necrosis,
apoptosis,
and
active
secretion,
all
which
offer
information
about
state
nature
tumor.
Comprehensive
profiling
been
enabled
by
methods
such
whole
genome
sequencing
methylation
analysis.
The
low
abundance
ctDNA
fraction
makes
alternative
techniques,
digital
PCR
targeted
next-generation
exome
sequencing,
more
valuable
accurate
for
mutation
detection.
There
are
numerous
clinical
applications
analysis,
non-invasive
liquid
biopsies
minimal
residual
disease
monitoring
to
detect
recurrence,
personalized
medicine
therapy
identification,
early
detection,
real-time
evaluation
therapeutic
response.
Integrating
analysis
routine
practice
creates
promising
avenues
successful
care,
from
diagnosis
treatment
follow-up.
